산화 스트레스 어세이 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2024-2032년)

The Global Oxidative Stress Assay Market was valued at USD 1.1 billion in 2023 and is projected to grow at 9.8% CAGR from 2024 to 2032. These assays are laboratory tests utilized to evaluate oxidative stress biomarkers in samples like blood, urine, or tissue. By assessing the balance between reactive oxygen species (ROS) and antioxidants, they offer valuable insights into cellular and tissue damage caused by oxidative stress.

The market is segmented into two main categories: instruments and consumables. Within the consumables segment, assay kits and reagents are expected to see significant growth, with the segment projected to reach USD 1.5 billion by 2032. Pre-packaged consumables, such as ready-to-use kits and reagents, simplify assay workflows and ensure consistency in results, making them highly accessible for laboratories across various expertise levels. This ease of use and reliability is driving broader adoption across the market.

Based on assay type, the market from the indirect assays segment was valued at USD 466.1 million in 2023. These assays are favored for their simplicity and user-friendliness, making them an attractive option for both researchers and clinicians. Their straightforward procedures help minimize errors and speed up the testing process, making them ideal for routine use in research and clinical laboratories.

The U.S. oxidative stress assay industry is expected to grow to USD 921.7 million by 2032. The increasing prevalence of chronic conditions, such as cardiovascular diseases, diabetes, and cancer, is driving the demand for effective diagnostic and therapeutic solutions. Additionally, the U.S. market benefits from a strong regulatory environment, with oversight from agencies such as the Food and Drug Administration (FDA). This regulation ensures that oxidative stress assays meet stringent safety and accuracy standards, boosting consumer trust and encouraging further market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic diseases
    • 3.2.1.2 Advances in diagnostic technologies
    • 3.2.1.3 Increasing awareness of antioxidant therapies
    • 3.2.1.4 Rising research in drug discovery and development
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of instruments
    • 3.2.2.2 Stringent regulatory challenges
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Instruments
• 5.3 Consumables
  • 5.3.1 Kits
  • 5.3.2 Reagents

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Indirect assays
  • 6.2.1 Protein-based assays
  • 6.2.2 Lipid-based assays
  • 6.2.3 Nucleic acid-based assays
• 6.3 Antioxidant capacity assays
  • 6.3.1 Glutathione assays
  • 6.3.2 Ascorbic acid assays
  • 6.3.3 Cell-based exogenous antioxidant assays
• 6.4 Enzyme-based assays
• 6.5 Reactive oxygen species-based assays

Chapter 7 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Enzyme-Linked Immunosorbent Assay (ELISA)
• 7.3 Flow cytometry
• 7.4 Chromatography
• 7.5 Microscopy
• 7.6 Other technologies

Chapter 8 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Cardiovascular disease
• 8.3 Respiratory diseases
• 8.4 Cancer
• 8.5 Diabetes
• 8.6 Other diseases

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Pharmaceutical and biotechnology industries
• 9.3 Academic research institutes
• 9.4 Contract Research Organizations (CROs)
• 9.5 Clinical laboratories
• 9.6 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 AMSBIO
• 11.2 ABCAM
• 11.3 Agilent Technologies
• 11.4 Biorbyt
• 11.5 Cayman Chemical
• 11.6 Cell Biolabs
• 11.7 Dojindo Molecular Technologies
• 11.8 Enzo Biochem
• 11.9 GenScript Biotech Corporation
• 11.10 LifeSpan BioSciences
• 11.11 Merck
• 11.12 Promega Corporation
• 11.13 QIAGEN
• 11.14 RayBiotech
• 11.15 Thermo Fisher Scientific